Dermata Therapeutics, Inc. (DRMA)
NASDAQ: DRMA · Real-Time Price · USD
1.215
-0.045 (-3.57%)
Apr 29, 2026, 2:06 PM EDT - Market open
Dermata Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Cash & Equivalents | 7.52 | 3.16 | 7.44 | 6.24 | 10.8 | |
| Cash & Short-Term Investments | 7.52 | 3.16 | 7.44 | 6.24 | 10.8 | |
| Cash Growth | 137.92% | -57.49% | 19.18% | -42.20% | 1935.97% | |
| Other Receivables | - | - | - | 0.01 | - | |
| Receivables | - | - | - | 0.01 | - | |
| Prepaid Expenses | 0.31 | 0.36 | 0.45 | 0.6 | 0.77 | |
| Other Current Assets | 0.03 | 0.01 | 0.09 | 0.09 | 0.06 | |
| Total Current Assets | 7.86 | 3.53 | 7.98 | 6.94 | 11.62 | |
| Accounts Payable | 0.46 | 0.81 | 0.87 | 0.5 | 0.52 | |
| Accrued Expenses | 1.18 | 1.16 | 0.76 | 0.43 | 1 | |
| Total Current Liabilities | 1.64 | 1.97 | 1.62 | 0.92 | 1.52 | |
| Common Stock | 0 | 0 | 0 | 0 | 0 | |
| Additional Paid-In Capital | 79.46 | 67.24 | 59.74 | 51.61 | 46.09 | |
| Retained Earnings | -73.23 | -65.68 | -53.39 | -45.59 | -35.98 | |
| Total Common Equity | 6.22 | 1.56 | 6.36 | 6.02 | 10.11 | |
| Total Liabilities & Equity | 7.86 | 3.53 | 7.98 | 6.94 | 11.62 | |
| Net Cash (Debt) | 7.52 | 3.16 | 7.44 | 6.24 | 10.8 | |
| Net Cash Growth | 137.92% | -57.49% | 19.18% | -42.20% | - | |
| Net Cash Per Share | 8.12 | 20.67 | 381.58 | - | - | |
| Filing Date Shares Outstanding | 4.02 | 0.54 | 0.04 | - | - | |
| Total Common Shares Outstanding | 2.66 | 0.25 | 0.03 | - | - | |
| Working Capital | 6.22 | 1.56 | 6.36 | 6.02 | 10.11 | |
| Book Value Per Share | 2.34 | 6.20 | 242.50 | - | - | |
| Tangible Book Value | 6.22 | 1.56 | 6.36 | 6.02 | 10.11 | |
| Tangible Book Value Per Share | 2.34 | 6.20 | 242.50 | - | - | |
Source: S&P Capital IQ. Standard template.
Financial Sources.